In AKI mouse models, induced by both cisplatin and ischemia‐reperfusion, stevioside treatment demonstrated significant renal protection, mitigating kidney damage markers, marking the first study to elucidate stevioside's therapeutic potential in AKI through GSDMD pathway inhibition. The gene discussed is GSDMD; the disease is acute kidney injury.